IMUX

7.0654.40%
MW

Michael Weston Bonney

Independent Chairman of the Board

Mr. Michael Weston Bonney, also known as Mike, B.A.is Strategic Advisor of Kineticos Life Sciences LLC. Mr. Weston Bonney is the Independent Chairman of the Board at Autolus Therapeutics plc since April 1, 2024. He is Chair of the Board at Immunic, Inc. from May 16, 2026. He serves as Chairman at Santa Ana Bio, Inc. since November 2025. He had been Chairman of the Board at Kaleido Biosciences, Inc. since October 13, 2020 until August 9, 2021. Mr. Bonney serves as a Chair at Dunad Therapeutics. since January 2023. Mr. Bonney has also served as Managing Director of Sasanoa Advisory Group Enterprises, LLC, a CEO advisory firm, since June 2019. Mr. Bonney served as Member of In Silico Patient Advisory Board at GNS Healthcare, Inc. since April 2020. He served as Executive Chair of Kaleido Biosciences, Inc since August 2018 until October 13, 2020 and served as its Director since 2017 until August 9, 2021. He served at Office of the Chief Executive Officer at Kaleido Biosciences, Inc since June 2020 until October 13, 2020. Mr. Bonney served as an Independent Director of Bristol-Myers Squibb Company since November 20, 2019 until August 3, 2021. Mr. Bonney served as Chief Executive Officer and Chair of the Board of Kaleido BioSciences, Inc. from June 2017 to August 2018. Mr. Bonney was a Director of Sarepta Therapeutics, Inc. since December 2017 until March 18, 2020. Mr. Bonney serves as an Advisor to the (prime minister) Cameron Commission on antimicrobial resistance (AMR). He served as Director of Syros Pharmaceuticals Inc. since June 2018 until March 3, 2020. He served as Director of X-Biotix Therapeutics, Inc. and Sarepta Therapeutics, Inc. Mr. Bonney was a Partner at Third Rock Ventures, LLC from January to July 2016. He possesses many years of operational, commercial and senior management experience in the biopharmaceutical industry. He served as the Chief Executive Officer of Cubist Pharmaceuticals LLC from June 11, 2003 to 2015 and served as its President from January 2002 to July 2, 2012 and Chief Operating Officer from January 2002 to June 2003. He served as the Chief Executive Officer and President of TerraGen Discovery, Inc. since June 11, 2003. He oversaw the most successful launch of an I.V. antibiotic in U.S. history. Mr. Bonney served as the Chief Operating Officer of TerraGen from January 2002 to June 2003. From 1995 to 2001, Mr. Bonney held various positions of increasing responsibility at Biogen MA Inc. including Vice President of Sales and Marketing from 1998 to 2001. At Biogen, he built the commercial infrastructure for the launch of AVONEX(R). He held various positions in sales, marketing and strategic planning at Zeneca Pharmaceuticals, ending his eleven-year career and served as its National Business Director. From 1984 to 1995, he advanced through sales, product management and sales management positions. Mr. Bonney demonstrated his leadership abilities by presiding over a sales group of over 1000 people and honed his bio-pharmaceutical administrative skills by launching key products and oversaw a major two-year process- reengineering program. Mr. Bonney joined the Alnylam Pharmaceuticals, Inc. in December 2014. He served as Executive Chairman at Alnylam Pharmaceuticals, Inc. since August 2, 2021 until January 2023 and served as its Director since December 2014 until December 02, 2025. He had been the Chairman of the Board of Alnylam Pharmaceuticals, Inc. since December 2015 until August 2, 2021. He served as the Chairman of Magenta Therapeutics, Inc. since November 2016 until August 3, 2021 and he previously served as Executive Chairman from November 2016 until June 2018 and served as Chairman at Bates College since 2010 until 2019. He has been a Trustee of Tekla Life Sciences Investors and Tekla Healthcare Investors since 2011. He is a Director of Gulf of Maine Research Institute since July 2019. Mr. Bonney served as a Director of Revolution Medicine from 2016 to 2017 and serves as Director at Tekla Capital Management and WhiteHead Institute for Biomedical Research. He has been a Director of Celgene Limited since April 14, 2015 and had been Director at Celgene Corporation since April 14, 2015 until November 15, 2019. Mr. Bonney serves as a Director of Manufacturers of America. Mr. Bonney served as Director of Global Blood Therapeutics, Inc since February 8, 2016 until June 20, 2017. He served as a Director of TerraGen Discovery, Inc. since June 11, 2003 and Cubist Pharmaceuticals LLC from June 11, 2003 to January 2015. He served as a Director of NPS Pharmaceuticals, Inc. from January 2005 to February 21, 2015. He also served as a Member of Biogen's clinical development review board. Mr. Bonney served as the Non-Executive Chairman of Cubist Pharmaceuticals LLC from January 1, 2015 to January 31, 2015. He served as a Director of Gulf of Maine Research Institute until June 16, 2017. Mr. Bonney has operational, commercial and senior management expertise in the biopharmaceutical industry. He focuses on the formation, development and strategy for new portfolio companies. He was involved in the creation of the GAIN act. He was a regional winner and national finalist (2013) in the life science segment of Ernst & Young's Entrepreneur of the Year; was a finalist (2011) in DJ/Morningside CEO of the Year and was recognized as the Top CEO in Massachusetts by the Boston Globe (2008). He serves on Board of Trustees of the non-profit Rare. He received the MASSBio Innovative Leadership Award in 2010. Mr. Bonney holds a BA Degree in Economics from Bates College.

Positions